Published in Medical Letter on the CDC and FDA, October 17th, 2004
According to a study from the United States, "Immune responses against tumor-associated antigens rely on efficient epitope presentation. The melanoma-associated antigen gp100 contains HLA-A*0201 ligands that are characterized by low to medium binding affinity, among which gp100209-217 is the most prominent. While this epitope is a natural T-cell target, it primes with low-efficiency T-cell responses during immunization. A modified gp100 epitope, gp100209-217T210M , that contains a Thr to Met substitution at...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.